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A B S T R A C T   
Primary biliary cholangitis (PBC) is an autoimmune disease characterized by progressive destruction of the 
intrahepatic bile ducts. The immunopathology of PBC involves excessive inflammation; therefore, negative 
regulators of inflammatory response, such as Monocyte Chemoattractant Protein-1-Induced Protein-1 (MCPIP1) 
may play important roles in the development of PBC. The aim of this work was to verify whether Mcpip1 
expression protects against development of PBC. Genetic deletion of Zc3h12a was used to characterize the role of 
Mcpip1 in the pathogenesis of PBC in 6–52-week-old mice. We found that Mcpip1 deficiency in the liver 
(Mcpip1fl/flAlbCre) recapitulates most of the features of human PBC, in contrast to mice with Mcpip1 deficiency in 
myeloid cells (Mcpip1fl/flLysMCre mice), which present with robust myeloid cell-driven systemic inflammation. In 
Mcpip1fl/flAlbCre livers, intrahepatic bile ducts displayed proliferative changes with inflammatory infiltration, 
bile duct destruction, and fibrosis leading to cholestasis. In plasma, increased concentrations of IgG, IgM, and 
AMA autoantibodies (anti-PDC-E2) were detected. Interestingly, the phenotype of Mcpip1fl/flAlbCre mice was 
robust in 6-week-old, but milder in 12–24-week-old mice. Hepatic transcriptome analysis of 6-week-old and 24- 
week-old Mcpip1fl/flAlbCre mice showed 812 and 8 differentially expressed genes, respectively, compared with 
age-matched control mice, and revealed a distinct set of genes compared to those previously associated with 
development of PBC. In conclusion, Mcpip1fl/flAlbCre mice display early postnatal phenotype that recapitulates 
most of the features of human PBC.   
1. Introduction 
Primary biliary cholangitis (PBC) is an autoimmune, chronic 
cholestatic liver disease, characterized by a slow, progressive destruc-
tion of the intrahepatic bile ducts. Features of the disease include 
inflammation leading to the destruction of small- and medium-sized 
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intrahepatic bile ducts, development of fibrosis, and granulomas, and 
may lead to cirrhosis [1]. The prevalence of PBC ranges from 1.91 to 
40.2 per 100,000 people, with the important, yet unexplained, hallmark 
of predominance in females [2,3]. Unfortunately, the factors leading to 
PBC are not fully understood. Environmental stimuli, as well as inter-
acting immunogenetic and epigenetic risk factors, have been proposed 
contributors [4,5]. For example, pollution, tobacco smoke, toxin expo-
sure, or infectious agents (e.g., E. coli) are considered promoters of PBC 
development [3,6,7]. Additionally, it has been shown by many studies 
that family history and genetic predisposition are important factors in 
PBC risk and etiology. In monozygotic twins, the concordance rate is 
63%, and for the first-degree relatives of PBC patients, concordance is 
4% [3,6]. 
The main symptoms of PBC are not specific and include fatigue, skin 
hyperpigmentation, pruritus (itchy skin), hepatosplenomegaly, and 
xanthelasmas. Portal hypertension or jaundice may also occur in PBC. 
However, 20%–60% of PBC cases are diagnosed in asymptomatic pa-
tients based on the detection of antimitochondrial autoantibodies 
(AMA), which are associated with the elevation of IgM and cholestatic 
biochemistry, and then confirmed by the presence of specific bile duct 
pathology assessed via liver biopsy [6]. The presence of AMA, targeted 
to pyruvate dehydrogenase (PDC-E2), branched chain 2-oxo-acid de-
hydrogenase and 2-oxo-glutaric acid dehydrogenase is a highly specific 
marker that is identified in about 95% of patients with PBC [7]. 
Although it is clear that the pathophysiology of PBC is linked to an 
intense autoimmune response directed against biliary epithelial cells, 
the mechanism of biliary destruction remains enigmatic. The immuno-
pathology of PBC is consistent with the dysregulation of both adaptive 
and innate immunity, resulting in excessive activity of various inflam-
matory cells [8]. Several specific mechanisms have been postulated, 
including IL-12-JAK-STAT4 signaling, Th1 T cell polarization, CD80 or 
IFN-gamma-dependent pathways, as well as the involvement of liver- 
infiltrating autoreactive T cells (CD4+ T cells, CD8+ T cells, natural 
killer T cells, and B cells) [1]. 
The activation of inflammatory cells is controlled on transcriptional 
and posttranscriptional levels by Monocyte Chemoattractant Protein- 
Induced Protein 1 (MCPIP1, alias Regnase1), which is involved in 
negative regulation of inflammation through its endonuclease activity 
[9,10] that shortens the half-life of selected pro-inflammatory cytokine 
transcripts (e.g., IL-1β, IL-6, IL-8) and mitigates their function [11–13]. 
The anti-inflammatory properties of MCPIP1 have been confirmed in 
vivo [9,14–16], but it is not known whether MCPIP1 controls the auto-
immune response in patients with PBC. Recently, Sun et al. described a 
protective role of Mcpip1 in liver recovery after ischemia/reperfusion 
(I/R) injury, indicating that Mcpip1 functions to ameliorate liver dam-
age, reduce inflammation, prevent cell death, and promote tissue 
regeneration, but authors did not study the role of MPCIP1 in the context 
of autoimmune liver disease [17]. 
To verify the hypothesis that Mcpip1 expression protects against the 
development of autoimmune liver disease, we generated mice lacking 
Mcpip1 in liver cells (Mcpip1fl/flAlbCre). Their phenotype recapitulated 
features of human biliary cholangitis as evidenced by increased levels of 
immunoglobulins (IgG, IgM) as well as AMA and anti-nuclear autoan-
tibodies (ANA, anti-PDC-E2, anti-gp-210, respectively), liver fibrosis, 
inflammation, and destruction of intrahepatic bile ducts that led to 
cholestasis. 
2. Materials and methods 
2.1. Animals and genotyping 
Animals were housed in ventilated cages under specific pathogen- 
free conditions in a temperature-controlled environment with a 14/ 
10 h light/dark cycle and fed ad libitum with standard laboratory chow 
food (Altromin). To obtain hepatocyte-specific knockout of the Zc3h12a 
gene encoding Mcpip1, Zc3h12alox/lox mice (Mcpip1fl/fl), with loxp sites 
flanking exon 3 of the Zc3h12a gene [16], were crossed with liver- 
specific Cre-expressing transgenic mice (AlbCre tg/+, Jackson Labora-
tory). The mice were designated as Mcpip1fl/flAlbCre. Deletion of Mcpip1 
in leukocytes of myeloid origin was achieved after crossing Mcpip1fl/fl 
mice with a LysM-Cre expressing strain (LysMCre tg/+, Jackson Labora-
tory). The mice were designated Mcpip1fl/flLysMCre. For genotyping, 
DNA was extracted from tail tissue using the KAPA Mouse Genotyping 
Kit (KAPA Biosystems) according to the manufacturer’s instructions. 
Genotyping for loxp insertion was performed by PCR using the following 
primers: GCCTTCCTGATCCTATTGGAG (wild-type), GAGATGGCG-
CAGCGCAATTAAT (knock-out), and GCCTCTTGTCACTCCCTCCTCC 
(common). Genotyping for AlbCre tg/+ was conducted with the following 
primers: TGCAAACATCACATGCACAC (wild-type), GAAGCA-
GAAGCTTAGGAAGATGG (mutant), and TTGGCCCCTTACCATAACTG 
(common), and genotyping for LysMCre was performed using TTA-
CAGTCGGCCAGGCTGAC (wild-type), CCCAGAAATGCCAGATTACG 
(mutant), and CTTGGGCTGCCAGAATTTCTC (common). The Local 
Animal Ethical Commission approved all experiments. 
2.2. Collection of tissue and organs 
Blood and organs were always harvested between 9 a.m. and 12.00 a. 
m. Anesthesia with ketamine and xylazine was followed by blood 
collection from the orbital sinus. Next, livers and spleens were dissected, 
weighted and liver lobes were divided for RNA and protein isolation 
(lobus hepatis sinister medialis and sinister lateralis) and histology 
(lobus hepatis dexter medialis and dexter lateralis, lobus hepatis 
caudatus). 
2.3. Histological evaluation of liver pathology in Mcpip1fl/flAlbCre mice 
Liver samples obtained from male and female mice of different ages 
were fixed in 4% buffered formalin and processed through the standard 
paraffin embedding method. Sections of 5 μm were stained with he-
matoxylin and eosin (HE) for general histology and Picro Sirius Red 
(PSR) for collagen deposition, and then visualized using a standard light 
microscope (Olympus BX51; Olympus Corporation). Qualitative evalu-
ation of liver samples was performed under 200× and 400× magnifi-
cation. For quantitative analysis of fibrosis, PSR-stained sections were 
imaged under 100× magnification and the degree of collagen deposition 
was analyzed using the Ilastik segmentation toolkit and Fiji ImageJ 
software (NIH, Bethesda, MD, United States). The number of bile ducts 
was calculated from counts within 10 randomly chosen portal areas per 
liver section, under 200× magnification in a blinded fashion, using a 
standard light microscope (Olympus BX41; Olympus Corporation). 
2.4. Immunohistochemical staining 
5 μm paraffin sections were deparaffinated with standard protocol, 
followed by heat-mediated epitopes retrieval. For staining the EnVision 
G2 Doublestain System, Rabbit/Mouse (DAB+/Permanent Red) Kit 
(Dako) was used. The following anti-mouse primary antibodies were 
used: Cytokeratin 19 (Abcam), Cd3 (Bio-Rad), F4/80 (NovusBio), Ly6C 
(Serotec), B220 (Invitrogen). Next, liver samples were mounted with 
glycerol mounting medium (Dako), and examined with a Leica DMI6000 
B microscope (Leica Microsystems). For quantitative analysis, cells were 
counted in 10 high power fields from 5 mice in the group. Samples 
stained with anti-mouse Ck19 antibodies were additionally counter-
stained with Mayer’s hematoxylin (Sigma). 
2.5. Transcriptome sequencing 
Prior to library preparation, RNA sample integrity was evaluated and 
concentration was measured using an Agilent 2100 Bioanalyzer with an 
RNA 6000 Pico Kit (Agilent). Libraries for 16 samples were prepared 
using the Ion AmpliSeq™ Transcriptome Mouse Gene Expression Kit, 
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which covers over 20,000 mouse RefSeq genes in a single assay. Li-
braries were prepared according to the manufacturer’s protocol using 
50 ng of total RNA as input. Sixteen barcoded libraries were combined 
and pooled in equimolar concentrations and subsequently sequenced on 
two chips from the Ion PI Chip Kit v3 using an Ion Proton Sequencer and 
Ion PI Hi-Q Sequencing 200 chemistry. The primary bioinformatic an-
alyses, including filtering and alignment of reads, were carried out using 
Torrent Suite Server v5.10.0. Subsequently, reads were counted and 
subjected to differential expression analysis using the DESeq2 package 
(with default parameters) implemented in R version 3.3.3. P-values for 
differentially expressed genes were corrected for multiple comparisons 
using the Benjamini-Hochberg approach and results with corrected p- 
values <0.05 were considered significant. Functional annotation of 
differentially expressed genes (≥ 1.2-fold change) was performed using 
bioinformatic tools available via the Database for Annotation, Visuali-
zation and Integrated Discovery (DAVID; version 6.8; https://david. 
ncifcrf.gov/home.jsp). Gene lists were searched using Ensembl gene 
annotation (ENSEMBL_GENE_ID), with the Mus musculus background 
dataset used for analyses. Selected genes were mapped to Biological 
Process (BP) Gene Ontology (GO) terms. Venn diagrams were created 
using the InteractiVenn tool [18]. Principal component analysis (PCA) 
was conducted for RNA-Seq data to demonstrate differential gene 
expression in the analyzed cell types. PCA analysis and subsequent plot 
generation were conducted using DESeq2 and ggplot2 libraries in R. 
2.6. Statistical analysis 
Results are expressed as mean ± SEM. The exact number of experi-
ments or animals used is indicated in figure legends. Two-tailed Stu-
dent’s t-test was used for comparison of two groups, and one-way 
ANOVA with Bonferroni post hoc test was applied for comparison of 
multiple groups. Statistical significance is indicated by asterisks in fig-
ures, with the following definitions: * p < 0.05; ** p < 0.01; *** p <
0.001. 
For further details regarding the materials and methods used, please 
refer to the supplementary information. 
3. Results 
3.1. Development of liver-specific Zc3h12a-deficient mice 
To study the function of Mcpip1 protein in vivo, we generated 
Mcpip1fl/flAlbCre knockout mice which lack the Zc3h12a gene in liver 
cells. As previously described by Li and colleagues [16], murine em-
bryonic stem cells were genetically modified to obtain a loxp knock-in 
flanking the 3rd exon of the Zc3h12a gene. After generation of 
chimeric mice and a series of backcrosses, the C57BL/6N Zc3h12afl/fl 
mice were obtained (Fig. S1A). Control Mcpip1fl/fl and Mcpip1fl/flAlbCre 
mice were selected after standard genotyping (Fig. S1B), and deletion of 
the Zc3h12a gene was confirmed in Mcpip1fl/flAlbCre mice at both the 
RNA and protein levels (Fig. S1C,D). The knockout mice showed 
diminished Zc3h12a expression in the liver and primary hepatocytes, 
but not in the heart and lungs, confirming liver specificity of Mcpip1 
silencing (Fig. S1C,D). 
3.2. General characteristics of Mcpip1fl/flAlbCre mice 
Mcpip1fl/flAlbCre mice were born at the expected Mendelian ratio and 
had no gross abnormalities or impairment in general fitness (mobility, 
activity (lethargy), alopecia, presence of wounds and piloerection) up to 
52 weeks of age compared to Mcpipfl/fl mice (data not shown). There 
were no differences in body mass of Mcpip1fl/flAlbCre versus control 
mice, however, Mcpip1fl/flAlbCre animals were characterized by hepa-
tomegaly and splenomegaly (Fig. S1E-G). Blood morphology parameters 
of 6, 24, and 52-week-old Mcpip1fl/flAlbCre animals did not differ 
significantly from Mcpip1fl/fl counterparts (Table 1). Alkaline phos-
phatase (ALP) activity and concentration of total bile acids (TBA) in the 
serum of 6-week-old Mcpip1fl/flAlbCre mice were both significantly 
higher than in control animals (Table 2). In 52-week-old Mcpip1fl/ 
flAlbCre mice, TBA was also higher compared with that of age-matched 
controls, but the difference did not reach significance (p = 0.083). In 
contrast to young and old Mcpip1fl/flAlbCre mice, 24-week-old Mcpip1fl/ 
flAlbCre mice did not show any differences in biochemical parameters 
compared with their Mcpip1fl/fl counterparts (Table 2). 
3.3. Histological and serological pathology of Mcpip1fl/flAlbCre mice 
recapitulates human primary biliary cholangitis 
Mcpip1fl/flAlbCre mice at 6–52 weeks of age, but not Mcpip1fl/fl mice, 
displayed characteristic liver pathology, including active and progres-
sive proliferation of intrahepatic bile ducts accompanied by extensive 
parenchymal inflammation and fibrosis, along with fibrosis in portal 
areas, all at various intensities depending on age (Fig. 1, S3-S5). Inter-
estingly, first symptoms of PBC in Mcpip1fl/flAlbCre mice were already 
detected in 10-day-old pups (Fig. S2). 
All features of intrahepatic bile duct pathology were extensive in 6- 
week-old Mcpip1fl/flAlbCre mice, however, at 24 weeks of age, histo-
pathological changes were less severe in the liver parenchyma. By 52 
weeks of age, the histopathological features of PBC were modestly re- 
intensified in Mcpip1fl/flAlbCre mice (Fig. 1C,D,G,H). 
In 6-week-old Mcpip1fl/flAlbCre mice, active and intensive collagen 
deposition was associated with extensive bile duct hyperplasia and 
inflammation (Fig. 1E, S4). At the ages of 12 and 24 weeks, proliferation 
and inflammatory processes diminished temporarily and the area of 
fibrotic tissue was reduced (Fig. 1F,G, S4). However, recurrence of 
intrahepatic and periportal cholangiocytes’ proliferation with inflam-
matory infiltration in livers of 52-week-old animals led to reactivation of 
collagen deposition (Fig. 1H, S4). The entire spectrum of features of 
Table 1 
Blood counts of Mcpip1fl/fl and Mcpip1fl/flAlbCre mice.  
Component 6 weeks 24 weeks 52 weeks 
Mcpip1fl/fl Mcpip1fl/flAlbCre Mcpip1fl/fl Mcpip1fl/flAlbCre Mcpip1fl/fl Mcpip1fl/flAlbCre 
Erythrocytes (*1012/L) 9.19 ± 0.62 8.98 ± 0.83 9.73 ± 0.85 9.28 ± 0.61 10.45 ± 0.23 9.76 ± 0.26 
Hemoglobin (g/dL) 15.03 ± 0.63 14.83 ± 0.98 14.52 ± 1.10 14.13 ± 0.93 14.75 ± 0.32 14.14 ± 0.31 
Hematocrit (%) 46.19 ± 2.64 45.68 ± 4.28 45.67 ± 4.76 44.01 ± 2.57 51.17 ± 1.29 48.70 ± 1.17 
MCV (fl) 50.43 ± 1.27 51.00 ± 0.82 46.83 ± 1.47 47.89 ± 1.17 49.17 ± 0.70 49.78 ± 0.57 
MCH (pg) 16.39 ± 0.48 16.60 ± 0.42 14.93 ± 0.42 15.28 ± 0.19 14.12 ± 0.21 14.50 ± 0.20 
MCHC (g/dL) 32.59 ± 0.81 32.53 ± 1.07 31.85 ± 0.87 31.89 ± 0.51 28.82 ± 0.27 29.03 ± 0.19 
Platelets (*109/L) 749.0 ± 125.8 672.8 ± 80.1 989.3 ± 192.2 1051.3 ± 248.1 1314.6 ± 91.8 1342.3 ± 192.4 
Leukocytes (*109/L) 3.74 ± 0.53 5.17 ± 0.56 5.97 ± 0.66 6.46 ± 0.65 5.65 ± 0.31 6.64 ± 0.82 
Lymphocytes (*109/L) 2.09 ± 0.30 3.33 ± 0.29 3.90 ± 0.86 3.87 ± 1.16 3.88 ± 0.34 4.84 ± 1.07 
Granulocytes (*109/L) 1.51 ± 0.20 1.48 ± 0.28 2.53 ± 0.56 2.37 ± 0.38 1.83 ± 0.11 2.74 ± 1.48 
Monocytes (*109/L) 0.14 ± 0.04 0.28 ± 0.03 0.25 ± 0.04 0.31 ± 0.08 0.30 ± 0.04 0.40 ± 0.24 
Data are presented as mean ± SEM, for Mcpip1fl/fl n = 5 and for Mcpip1fl/flAlbCre n = 8. 
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intrahepatic bile duct pathology was present in 52-week-old Mcpip1fl/ 
flAlbCre mice, as shown in Fig. 2A-H. The extensive proliferation of bile 
ducts in the liver parenchyma and portal areas was accompanied by bile 
duct epithelium disruption, inflammation, and fibrosis, resulting in 
lumen obstruction and bile duct destruction (Fig. 2A-C). Eventually, the 
closure of intrahepatic bile duct lumen, bile acid deposition in hepato-
cytes, and formation of small granulomas were observed (Fig. 2D-F). 
To further assess the similarities between the phenotype of Mcpip1fl/ 
flAlbCre mice and the characteristics of PBC in humans, levels of total 
IgG, IgM, and specific AMA and ANA were measured. IgG and IgM 
concentrations were higher in 6 and 24-week-old Mcpip1fl/flAlbCre ani-
mals compared to Mcpip1fl/fl counterparts (Fig. 2I,J). Additionally, 
60–90% of Mcpip1fl/flAlbCre mice had higher plasma concentrations of 
anti-PDC-E2 mitochondrial autoantibodies than control counterparts 
(Fig. 2K). Incidence of anti-gp-210 nuclear autoantibodies, was elevated 
in 12-week-old Mcpip1fl/flAlbCre mice and reached 90% (Fig. 2L). 
Mcpip1fl/flAlbCre mice of all ages showed increased leukocytes infil-
tration into the liver parenchyma in comparison to Mcpip1fl/fl controls 
(Fig. 3A-C). Lymphocytes T were predominant population of leukocytes 
infiltration in 6-week-old mice, while 24-week-old Mcpip1fl/flAlbCre 
animals were characterized by additional accumulation of lymphocytes 
B, macrophages and neutrophils. Finally, only in 6-week-old Mcpip1fl/ 
flAlbCre mice expression of cholangiocytes’ marker – cytokeratin 19 
(Ck19) – was significantly increased (Fig. 3D-F). 
To verify whether systemic inflammation caused by lack of Mcpip1 
protein in myeloid cells might also lead to PBC development, Mcpip1fl/ 
flLysMCre mice were analyzed. Features of human PBC were not observed 
in Mcpip1fl/flLysMCre mice, despite the presence of robust myeloid cell- 
driven systemic inflammation (Fig. S6). 
3.4. Male and female Mcpip1fl/flAlbCre mice have the same pathological 
features 
In humans, PBC is disease with high predominance in females. We 
therefore compared the phenotype of female and male Mcpip1fl/flAlbCre 
mice. Histological comparison of liver sections from 6, 12, and 24-week- 
old Mcpip1fl/flAlbCre mice revealed no differences in the development of 
pathology between female and male mice. All characteristic features of 
intrahepatic bile duct pathology demonstrated in male Mcpip1fl/flAlbCre 
mice were also present in female Mcpip1fl/flAlbCre mice, including a 
similar pattern of collagen deposition in the liver (Fig. S7A). There was 
also no difference between male and female Mcpip1fl/flAlbCre mice in 
plasma levels of anti-PDC-E2 and anti-gp-210 autoantibodies (Fig. S7B). 
3.5. Transcriptome changes in Mcpip1-depleted primary hepatocytes 
To better understand the molecular mechanisms responsible for the 
robust PBC phenotype in 6-week-old Mcpip1fl/flAlbCre mice and its 
downregulation in 24-week-old Mcpip1fl/flAlbCre mice, the tran-
scriptome of isolated primary hepatocytes was analyzed. Differential 
gene expression analysis followed by calculation of p-values revealed 
that, in 6 and 24-week-old Mcpip1fl/flAlbCre mice, there were 812 and 8 
differentially expressed genes (DEGs), respectively, compared with their 
respective age-matched controls. 
In hepatocytes derived from 6-week-old Mcpip1fl/flAlbCre mice, 688 
DEGs were upregulated and 124 were downregulated (Table S1 in the 
Supplementary Material). As shown in Fig. 4, upregulated genes were 
related to cell cycle control (e.g., cell division, mitotic nuclear division, 
cell cycle, positive regulation of cell proliferation), regulation of 
inflammation (e.g., inflammatory response, immune response, cytokine- 
mediated signaling, IL-1β and IL-6 production), and extracellular matrix 
biosynthesis (e.g., extracellular matrix and collagen fibril organization, 
collagen biosynthesis, extracellular matrix constituent secretion). 
Downregulated genes were related to lipid metabolism (e.g., lipid 
metabolic processes, fatty acid (FA) β-oxidation, FA and cholesterol 
metabolic processes, FA transport, negative regulation of lipid storage), 
oxidation-reduction processes, glucose homeostasis, and organic anion 
transport (Fig. 4). 
In hepatocytes from 24-week-old Mcpip1fl/flAlbCre mice, only 8 genes 
were differently expressed compared to age-matched control mice 
(upregulated in Mcpip1fl/flAlbCre: Lpin1, Lrp6, and Tmc7; downregulated 
in Mcpip1fl/flAlbCre: Cela1, Ppdpf, Asap1, Lect2, and Pla2g16; Table S2 in 
the Supplementary Material). 
The striking difference between the transcriptomes of 6 and 24- 
week-old Mcpip1fl/flAlbCre versus their respective controls was also 
confirmed by direct comparison of the transcriptomes of hepatocytes 
from 6 and 24-week-old Mcpip1fl/flAlbCre mice, which showed 725 
DEGs, with 538 upregulated and 187 downregulated (Fig. S8, Table S3 
in the Supplementary Material). This comparison revealed similar 
enhanced processes (mitotic nuclear division, cell cycle, and cell divi-
sion) when hepatocytes isolated from 6-week-old control and knockout 
mice were compared. 
4. Discussion 
We have, to our knowledge, been the first to demonstrate that the 
phenotype of Mcpip1fl/flAlbCre mice recapitulates most features of 
human PBC (Table 3). On a histopathological level, Mcpip1fl/flAlbCre 
mice displayed intrahepatic bile duct pathology that included active 
proliferative changes, inflammatory infiltration, bile duct epithelium 
disruption, small granuloma formation, and significant and progressive 
liver fibrosis in the parenchyma and portal areas. On a functional level, 
Mcpip1fl/flAlbCre mice showed cholestasis. Autoimmune response, a 
characteristic feature of PBC, was also detected in Mcpip1fl/flAlbCre 
mice, as demonstrated by increased plasma concentrations of IgG and 
IgM, as well as AMA and ANA autoantibodies (anti-PDC-E2, anti-gp- 
210). As Mcpip1 deficiency in myeloid cells (Mcpip1fl/flLysMCre mice) 
did not result in features of PBC, we concluded that Mcpip1, specifically 
in the liver, is a negative regulator of autoimmune response and may 
protect against PBC development. Importantly, our results showed that 
Mcpip1fl/flAlbCre mice had robust postnatal symptomatology, displayed 
a mild phenotype in middle age, and seem to regain PBC features in 
older age. Transcriptomic analysis of primary hepatocytes revealed a 
distinct set of genes compared to those previously linked to PBC, and 
Table 2 
Blood biochemistry of Mcpip1fl/fl and Mcpip1fl/flAlbCre mice.  
Component 6 weeks 24 weeks 52 weeks 
Mcpip1fl/fl Mcpip1fl/flAlbCre Mcpip1fl/fl Mcpip1fl/flAlbCre Mcpip1fl/fl Mcpip1fl/flAlbCre 
ALT (U/L) 46.60 ± 6.91 50.36 ± 2.57 53.64 ± 8.28 48.39 ± 7.59 38.14 ± 6.37 92.40 ± 33.58 
Albumin (g/dL) 3.33 ± 0.07 3.36 ± 0.05 3.15 ± 0.11 3.19 ± 0.09 3.64 ± 0.07 3.46 ± 0.13 
AST (U/L) 125.9 ± 15.7 119.5 ± 12.6 141.8 ± 17.4 152.5 ± 10.8 116.5 ± 16.6 180.3 ± 46.9 
Bilirubin (mg/dL) 0.06 ± 0.01 0.05 ± 0.01 0.10 ± 0.03 0.08 ± 0.01 Not detected Not detected 
Cholesterol (mg/dL) 99.11 ± 6.74 111.10 ± 3.01 95.14 ± 7.15 105.40 ± 5.73 93.25 ± 8.52 92.00 ± 9.63 
ALP (U/L) 149.0 ± 12.0 287.7 ± 43.2 ** 72.4 ± 1.8 75.1 ± 4.5 83.1 ± 4.6 108.3 ± 21.8 
TBA (μmol/L) 7.3 ± 3.1 111.7 ± 28.2 ** Not analyzed Not analyzed 40.9 ± 23.6 90.1 ± 21.6 p =0.083 
Data are presented mean ± SEM, for Mcpip1fl/fl n = 5 and for Mcpip1fl/flAlbCre n = 8. 
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identified distinct transcriptomes for early and chronic phases of PBC. 
Altogether, Mcpip1fl/flAlbCre mice represent a unique model that closely 
mimics PBC in humans (see Table 3 for summary) and has significant 
potential to increase insight into the pathophysiology of PBC. 
Previously described murine models of PBC, including genetically 
modified models, xenobiotic immunized models, and infection-triggered 
models display some important features of PBC, such as the presence of 
AMA, elevated levels of IgG and IgM, portal lymphocyte infiltration, and 
bile duct destruction [19]. However, they do not recapitulate all features 
of PBC; for example, other mouse models do not display progressive 
fibrosis, a central clinical feature that informs prognosis, including 
morbidity and mortality, in human PBC patients [19]. Although 
Mcpip1fl/flAlbCre mice do not show female predominance of PBC fea-
tures, which has been observed in only one PBC model (IFNγ-ARE-Del 
mice) [20], the Mcpip1fl/flAlbCre mouse model has the advantage of 
clinical relevance via its unambiguous histopathological features and 
full spectrum of PBC-associated pathological changes that are not 
comprehensively present in any previously described model (Figs. 1, 2, 
S4, S5). Importantly, fibrosis was present in 100% of Mcpip1fl/flAlbCre 
mice, compared to approximately 50% of IL-12p35− /− ;dnTGFβRII 
double mutant mice [21]. Another unique feature of Mcpip1fl/flAlbCre 
mice is the robust postnatal PBC phenotype followed by remission in 
middle age, that is not driven by systemic inflammation, but by intrinsic 
liver-derived pathology. Although it is not known whether PBC in 
humans has MCPIP1-driven pathogenesis, peak incidence of PBC in 
humans occurs in the fifth decade of life; timing that seems compatible 
with the mild phenotype in middle-aged Mcpip1fl/flAlbCre mice. 
Mcpip1fl/flAlbCre mice are prone to PBC development, however it does 
not progress to fully-blown complications in 52-week-old mice. Lack of 
Mcpip1 in liver cells triggers this disease acting as a ‘first-hit’ that must 
be apparently followed by a ‘second-hit’ for the development of PBC into 
fully-blown phenotype in older mice. This seem in line with the number 
of known factors that precipitate PBC in humans [4,5,22]. In this regard, 
it would be tempting to test if Mcpip1fl/flAlbCre mice subjected to known 
PBC risk factors (toxins, chemicals, inflammatory factors), will respond 
with accelerated disease progression after exposure. 
The Mcpip1fl/flAlbCre mouse model of PBC presented here differs 
from other models on both the phenotype and genomic levels. Previ-
ously, PBC mouse model development was driven by alteration of 
function of various genes, including Ifng [20], Tgfbr2 [23], Il2ra (IL- 
2Rα− /− ) [24], Foxp3 [25], Il12a [21] and Slc4a2 [26], yet none of these 
genes was found to be differentially expressed in hepatocytes isolated 
from Mcpip1fl/flAlbCre mice. Indeed, Mcpip1fl/flAlbCre mice displayed a 
unique set of DEGs in hepatocytes, with a strikingly distinct profile of 
DEGs in early and chronic phases of the disease in 6 and 24-week-old 
Mcpip1fl/flAlbCre mice, respectively. 
In 6-week-old Mcpip1fl/flAlbCre mice with early phase PBC, we 
identified enhanced expression of many genes involved in cell prolifer-
ation (e.g., Hgf, Tgfb1, Wnt2), as well as genes involved in biliary 
development and cholangiocyte proliferation and important for biliary 
repair (e.g., Hgf, Pdgfa, Tgfb1, Bmp2, Mmp9), fibrosis (e.g., Tgfb1, Lpin1), 
inflammation (e.g., Il1a, Il1b, ccl2, Cxcl2, Cxcl12, S100a8, S100a9), or 
extracellular matrix organization (e.g., Mmp9, Col1a1, Col3a1). 
In contrast to early phase PBC with 812 DEGs, the chronic remission 
phase showed only 8 DEGs, including altered expression of Lrp6, Lect2, 
and Lipin-1. Low-density lipoprotein receptor-related protein 6 (Lrp6) 
linked with the Wnt/β-catenin signaling pathway was shown to regulate 
liver fibrosis [27]. Leukocyte cell-derived chemotaxin-2 (LECT2), orig-
inally identified as a hepatocyte-secreted chemokine [28] was identified 
as a prognostic indicator in acute liver failure [29,30]. Finally, Lipin-1 
(Lpin1), the only gene with significantly different expression in knockout 
cells at both time points, was shown to coactivate HNF4α and regulate 
fatty acid catabolism [31] and TGF-β-induced fibrogenesis [32]. 
Mcpip1fl/flAlbCre mice also showed altered expression of organic 
anion transporters encoding Organic anion transporting polypeptide 
1a1 (Oatp1a1 protein, Slco1a1 gene) and Organic anion transporter 2 
(Oat2 protein, Slc22a7 gene), which are involved in bile acid transport 
[33]. These changes are likely primary to the PBC phenotype in 
Mcpip1fl/flAlbCre mice and compatible with the changes in expression of 
other organic transporters, such as NTCP, OATP1B1, and OATP1B3 in 
humans with PBC [34]. 
Although the expression of multiple genes were altered by the 
deletion of Mcpip1 alone, it seems impossible to identify a single 
signaling pathway responsible for the observed PBC phenotype in 
Mcpip1fl/flAlbCre mice, and changes in expression of multiple genes and 
their interactions are likely responsible. Although some genes differ-
ently expressed in the remission phase could be linked to liver fibrosis 
and liver failure, their roles in this PBC phenotype remain to be estab-
lished, along with links between the early and chronic phases of PBC and 
the mechanisms of activation of the disease phenotype in aging 
Mcpip1fl/flAlbCre mice. 
Finally, although Mcpip1fl/flAlbCre mice develop PBC, the molecular 
mechanism leading to this phenotype have not been defined here and 
needs to be elucidated. Interestingly, Alb-Cre construct was shown to 
drive gene deletion not only in hepatocytes, but also in cholangiocytes, 
activated stellate cells and hepatoblasts [35]. Hepatoblasts are progen-
itor cells, that differentiate into both hepatocytes and cholangiocytes 
during liver development [36]. Murine liver starts to develop at em-
bryonic day 8.5 and between E13.5-E16.5 hepatoblasts begin to differ-
entiate into mature cells – hepatocytes and cholangiocytes [37]. 
Albumin expression in hepatoblasts starts around embryonic day 13.5, 
which means that by using Alb-Cre construct, deletion of gene should be 
achieved not only in hepatocytes, but also in cholangiocytes [36,37]. In 
line with this data, we detected depletion of Mcpip1 protein both in 
hepatocytes and cholangiocytes isolated from Mcpip1fl/flAlbCre mice 
(unpublished observations). Thus, the future studies should verify, 
whether lack of Mcpip1 protein in Mcpip1fl/flAlbCre mice is linked to a 
hepatocyte-driven or cholangocyte-driven mechanism leading to chol-
angiocytes’ pathology and PBC development. Establishment of molec-
ular link between Mcpip1 and PBC would be possible, for example by 
testing phenotype of mice with deletion of Mcpip1 only in chol-
angiocytes but not in hepatocytes. 
Fig. 1. Progression of intrahepatic bile duct pathology in 
the liver parenchyma of 6 to 52- week-old Mcpip1fl/flAlbCre 
male mice. 
Proliferative changes in intrahepatic bile ducts with in-
flammatory infiltration predominate in young (6-week- 
old) mice leading to bile duct destruction, intraductal 
obstruction, and extensive fibrosis. At the age of 24 weeks, 
the processes of proliferation, inflammation, and collagen 
deposition were reduced, while aged mice (52-week-old) 
developed new foci of cholangiocyte proliferation accom-
panied by active fibrotic areas. Magnification 200×, HE 
(A-D) and PSR (E-H) staining. HE, hematoxylin and eosin; 
PSR, picrosirius red. For Mcpip1fl/fl n = 5 and for Mcpip1fl/ 
flAlbCre n = 10.   
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Fig. 2. Characterization of hallmarks of primary biliary cholangitis in Mcpip1fl/flAlbCre mice. 
HE staining of 52-week-old mice showing (A) Proliferation of intrahepatic bile ducts with associated parenchymal inflammation; (B) Epithelial destruction of 
intrahepatic bile ducts (black arrows) and extensive fibrosis of parenchyma; (C) Resolution of inflammation in intrahepatic bile ducts involving macrophages (black 
arrows); (D) Dysplasia of cholangiocytes with associated intraductal obstruction of intrahepatic bile ducts (asterisks); (E) Cholestasis and bile acid deposition in 
hepatocytes; (F) Small granuloma (white arrows indicate hepatocyte necrosis), magnification 400×. (G) Collagen area in the liver of 6, 12, 24, and 52-week-old 
Mcpip1fl/fl and Mcpip1fl/flAlbCre mice; (H) Number of bile ductules in livers per high power field (HPF); Concentrations of total IgG (I) and IgM (J) classes in 
plasma of 6 and 24-week-old Mcpip1fl/fl and Mcpip1fl/flAlbCre mice; Percentage of mice, with higher concentration of anti-PDC-E2 antimitochondrial autoantibodies 
(K) and anti-gp-210 antinuclear autoantibodies (L) compared to mean concentration in control Mcpip1fl/fl counterparts. For Mcpip1fl/fl n = 5 (Fig. 2), for Mcpip1fl/ 
flAlbCre n = 10 (Fig. 2A-G, I-L) and n = 5 (Fig. 2H). Data represent mean ± SEM, *p < 0.05, ***p < 0.001 vs. Mcpip1fl/fl; #p < 0.05, ##p < 0.01; ###p < 0.001 vs. 6 
weeks. HE, hematoxylin and eosin. 
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Fig. 3. Characterization of lymphocytic infiltration into livers of Mcpip1fl/flAlbCre mice. 
(A) Real-time PCR analysis of specific leukocytes markers: expression of Cd3e (T lymphocytes), Cd19 (B lymphocytes) and Adgre1 (macrophages) in livers of 6, 24 and 
52-week-old Mcpip1fl/fl and Mcpip1fl/flAlbCre mice; (B) representative immunohistological stainings and (C) quantitative analysis of leukocytes classes detected in 24- 
week-old control and Mcpip1fl/flAlbCre animals; (D) western blot analysis and (E) densitometric analysis of cytokeratin 19 (Ck19) protein level in 6, 24 and 52-week- 
old mice; (F) representative immunohistological stainings of Ck19 in 6 and 24-week-old control and Mcpip1fl/flAlbCre animals. For Mcpip1fl/fl and for Mcpip1fl/ 
flAlbCre n = 5. Data represent mean ± SEM, *p < 0.05, ***p < 0.001 vs. Mcpip1fl/fl. 
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Fig. 4. Transcriptome analysis of Mcpip1fl/fl and Mcpip1fl/flAlbCre primary hepatocytes. 
(A) PCA plot for RNA-Seq dataset demonstrating differential gene expression in all analyzed primary hepatocytes isolated from 6 and 24-week-old Mcpip1fl/fl (6w 
Mcpip1fl/fl, 24w Mcpip1fl/fl, respectively) and 6 and 24-week-old Mcpip1fl/flAlbCre mice (6w Mcpip1fl/flAlbCre, 24w Mcpip1fl/flAlbCre, respectively); (B) Venn diagram 
presenting the number of transcripts significantly up- and downregulated (adj. P-value <0.05) in 6-week-old Mcpip1fl/flAlbCre samples (6w Mcpip1fl/flAlbCre up/ 
down) and 24-week-old Mcpip1fl/fl (24w Mcpip1fl/fl up/down) in comparison to 6-week-old Mcpip1fl/fl controls (6w Mcpip1fl/fl); (C) Heat map showing differentially 
expressed genes selected from GO enrichment analysis; (D) GO enrichment analysis of genes differentially expressed in 6-week-old Mcpip1fl/fl and Mcpip1fl/flAlbCre 
primary hepatocytes. Scale is the –log10(P-value) of the enrichment score (p-value <0.05); (E) real-time PCR analysis of genes selected after NGS analysis. For 
Mcpip1fl/fl and Mcpip1fl/flAlbCre n = 4 (Fig. 4A-D) and n = 5 (Fig. 4E). Data represent mean ± SEM, *p < 0.05, **p < 0.01 vs. Mcpip1fl/fl. 
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Nevertheless, our work has demonstrated the novel role of Mcpip1 as 
a protein orchestrating biliary duct hemostasis and identified that the 
PBC phenotype results from Mcpip1 deficiency in the liver. Thus far, 
MCPIP1 is primarily known for its anti-inflammatory properties that are 
mediated via endonuclease activity and result in shortening the half-life 
of selected pro-inflammatory cytokine transcripts (e.g., IL-1β, IL-6, IL-8) 
and mitigating their function [9,10,13,38]. In a number of reports, the 
role of Mcpip1 in immune response has been demonstrated in vivo 
[9,27,39,40] and some reports suggested the involvement of Mcpip1 in 
autoimmune response; for example, in autoimmune gastritis and lupus 
[41]. Our study extends the knowledge of Mcpip1 as a regulator of 
autoimmune response in the liver, as we demonstrated that Mcpip1 
deficiency triggered autoimmunity against bile ducts and led to the PBC 
phenotype. 
In conclusion, our study demonstrated that Mcpip1 expression in the 
liver is a key protective factor against development of PBC. Mcpip1fl/ 
flAlbCre mice represent an excellent model to investigate the molecular 
mechanisms responsible for PBC development and to test novel treat-
ment strategies for PBC. 
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